Apyx Medical Inc
$ 3.54
-0.84%
24 Feb - close price
- Market Cap 146,476,000 USD
- Current Price $ 3.54
- High / Low $ 3.62 / 3.53
- Stock P/E N/A
- Book Value 0.16
- EPS -0.36
- Next Earning Report 2026-03-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.10 %
- ROE -1.68 %
- 52 Week High 4.50
- 52 Week Low 0.76
About
Apyx Medical Corporation, an energy technology company, develops, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. The company is headquartered in Clearwater, Florida.
Analyst Target Price
$6.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-19 | 2024-11-08 | 2024-08-08 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-16 |
| Reported EPS | -0.05 | 0.09 | -0.1 | -0.12 | -0.14 | -0.19 | -0.22 | -0.28 | -0.13 | -0.11 | -0.1 | -0.17 |
| Estimated EPS | -0.1033 | -0.09 | -0.12 | -0.16 | -0.19 | -0.2 | -0.21 | -0.18 | -0.11 | -0.07 | -0.13 | -0.14 |
| Surprise | 0.0533 | 0.18 | 0.02 | 0.04 | 0.05 | 0.01 | -0.01 | -0.1 | -0.02 | -0.04 | 0.03 | -0.03 |
| Surprise Percentage | 51.5973% | 200% | 16.6667% | 25% | 26.3158% | 5% | -4.7619% | -55.5556% | -18.1818% | -57.1429% | 23.0769% | -21.4286% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: APYX
2026-02-18 12:58:08
Apyx Medical announced its management will participate in The Citizens Life Sciences Conference on March 11, 2026, in Miami, FL. CEO Charlie Goodwin and CFO Matt Hill will host a fireside chat at 8:25 AM ET and engage in investor meetings throughout the day. The fireside chat will be live-streamed and available as a replay on the company's Investor Relations website.
2026-02-03 10:13:03
Apyx Medical Corporation (NASDAQ: APYX) shares have surged 26% in the last month, contributing to a 210% increase over the past year. Despite this growth, the company's revenue has been declining, and analysts forecast a 13% annual growth for the next three years, significantly lower than the industry's projected 132%. This disparity suggests that Apyx Medical's high price-to-sales ratio might not be sustainable given its subdued revenue forecasts.
2026-01-29 22:27:46
Apyx Medical (NASDAQ: APYX) will attend the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 10, 2026, in Snowbird, Utah. The company plans to showcase its Renuvion, J-Plasma, and FDA-cleared AYON Body Contouring System, which are supported by over 90 clinical documents. This participation follows a period of positive developments for Apyx, including recent revenue growth, international product approvals, and capital-raising activities.
2026-01-29 13:01:24
Apyx Medical Corporation announced its participation in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 10, 2026, in Snowbird, Utah. The company, known for its Renuvion and AYON Body Contouring System, invites investors to schedule meetings through BTIG representatives. Apyx Medical specializes in surgical aesthetics and leverages its expertise in unique waveforms for OEM agreements.
2026-01-13 09:28:44
Apyx Medical Corp. (APYX) is experiencing increased investor attention due to strong preliminary revenue results for Q4 and FY25, driven by the successful launch of AYON and increased demand in the U.S. Surgical Aesthetics segment. The company's Helium Plasma Technology, Renuvion and AYON, positions it well to capitalize on the surge in aesthetic surgical procedures, partly fueled by GLP-1 therapies. Despite a decline in OEM revenue, Apyx Medical's focus on advanced energy solutions and cosmetic applications is boosting growth and investor confidence, with its stock showing significant gains.
2026-01-13 04:31:00
Apyx Medical (APYX) is gaining investor interest following strong preliminary revenue results for Q4 and full-year 2025, driven by the commercial launch of AYON and increased demand in the U.S. Surgical Aesthetics segment. The company's Renuvion and AYON platforms are well-positioned to capitalize on the growing aesthetic surgical procedures market, partly fueled by GLP-1 therapies. While OEM revenue showed a decline year-over-year, the company's focus on advanced energy solutions and cosmetic applications is boosting growth and investor confidence, with its stock closing significantly higher.
